Full-Time

External Manufacturing Leader

Updated on 9/3/2026

Philips

Philips

Healthcare technology for diagnosis, care, wellness

Compensation Overview

$134k - $212k/yr

+ Annual Incentive Bonus + Stock Purchase Plan + 401k Match

No H1B Sponsorship

Wayzata, MN, USA

In Person

Residency within commuting distance to Plymouth, MN.

Bachelor's, Master's

Category
Operations & Logistics (1)
Required Skills
Six Sigma
Requirements
  • Five or more years of experience with a Bachelor's degree in engineering or three or more years of experience with a Master's degree
  • Ten or more years of progressive leadership experience in process development or manufacturing engineering preferred
  • Bachelor's or Master's degree in mechanical, biomedical, electrical or manufacturing engineering; Master’s degree preferred
  • Lean Manufacturing, Six Sigma or other continuous improvement certification
  • Demonstrated experience with electromechanical medical devices, strong knowledge of medical device regulations, quality systems and manufacturing validation requirements
  • Ability to manage cross-functional teams and influence at senior leadership levels
  • Ability to build scalable processes from development to high-volume manufacturing
Responsibilities
  • Lead execution across a complex global third-party manufacturing network within a highly regulated medical device environment
  • Strengthen infrastructure, elevate operational rigor, and build scalable processes across a global spend portfolio supporting external manufacturing partners
  • Manage multiple contract manufacturing organizations simultaneously—operating at both the site and strategic levels
  • Own the operational performance of a global network of third-party manufacturers, ensuring execution excellence across supply continuity, quality, cost, and delivery
  • Build a strong interdependent relationship across the CMO partners, and engage with site and business leadership with high degrees of collaboration
  • Driving End to End supply chain execution and performance accountability

Philips develops health technology across professional medical devices, connected care, and consumer health products. Its offerings include diagnostic imaging and image-guided therapy, patient monitoring and clinical informatics, and everyday wellness products like oral and personal care. The company increasingly delivers integrated solutions through a Healthcare-as-a-Service subscription model and long-term partnerships with hospitals and health systems. Its aim is to improve people’s health and well-being by making advanced health technology easier to access and integrate into care.

Company Size

N/A

Company Stage

IPO

Headquarters

Andover, Minnesota

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 4%, and Philips raised 2026 margin guidance.
  • June 2026 IntelliVue 6000 targets rural hospitals and ASCs with lower-cost enterprise monitoring.
  • August 2026 monitoring partnerships with Blue Spark, Caretaker, and Cuviva expand hospital-at-home reach.

What critics are saying

  • FDA consent decree still restricts Philips Respironics U.S. sleep-device manufacturing in 2026.
  • August 2026 Brilliance CT recall shows unresolved quality control failures across imaging hardware.
  • July 2026 China pressure and delayed U.S. orders hit bookings; margin depends on refunds.

What makes Philips unique

  • Philips spans imaging, monitoring, and consumer health, reducing dependence on any single procedure area.
  • Its open monitoring ecosystem links hospital and home devices through partner integrations and software.
  • Philips sells enterprise-grade workflows, not standalone hardware, through diagnostics and connected-care platforms.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Health Savings Account/Flexible Spending Account

Company News

PR Newswire
May 28th, 2026
Remote patient monitoring market to reach $117.9B by 2033 amid digital healthcare transformation

The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.

HIT Consultant
Apr 12th, 2024
Philips Respironics Reaches Final Agreement With Us Regulators On Sleep Apnea Device Recall

<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US,  subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024.  The company’s previously announced 2023-2025 financial outlook remains unchanged,  already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more

Goodrich Pharmacy
Jan 29th, 2024
Phillips Suspends U.S. Sales of CPAP, Ventilator Machines After Recall

Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.

YourLawyer.com
Mar 23rd, 2023
Sleep Apnea Patients Suffer While Waiting To Receive Their Repaired Philips CPAP Machines

In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.

Digital Journal
Jan 13th, 2023
Ultrasound Market Share | Market | Report | Analysis 2032 | Key Players: Fujifilm Holdings Corporation, Analogic Corporation, Siemens Healthcare among others

February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.